CO2023006514A2 - Agonista de receptor de melanocortina-4 amorfo - Google Patents

Agonista de receptor de melanocortina-4 amorfo

Info

Publication number
CO2023006514A2
CO2023006514A2 CONC2023/0006514A CO2023006514A CO2023006514A2 CO 2023006514 A2 CO2023006514 A2 CO 2023006514A2 CO 2023006514 A CO2023006514 A CO 2023006514A CO 2023006514 A2 CO2023006514 A2 CO 2023006514A2
Authority
CO
Colombia
Prior art keywords
amorphous
melanocortin
receptor agonist
formula
compound represented
Prior art date
Application number
CONC2023/0006514A
Other languages
English (en)
Inventor
Jongwon Park
Jin Ok Ham
Ho Yeon Lee
Ji Yoon Kim
Sung Won Kim
Seul Ah Chun
Sang Dae Lee
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2023006514A2 publication Critical patent/CO2023006514A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a un compuesto amorfo representado por la fórmula 1, un método para preparar el mismo, y una composición farmacéutica que comprende el mismo. El compuesto amorfo representado por la fórmula 1 de la presente invención se puede caracterizar por patrones XRD, perfiles DSC y/o perfiles TGA.
CONC2023/0006514A 2020-10-29 2023-05-17 Agonista de receptor de melanocortina-4 amorfo CO2023006514A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200142399 2020-10-29
PCT/KR2021/015467 WO2022092908A1 (ko) 2020-10-29 2021-10-29 무정형의 멜라노코르틴-4 수용체 작용제

Publications (1)

Publication Number Publication Date
CO2023006514A2 true CO2023006514A2 (es) 2023-07-31

Family

ID=81384115

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006514A CO2023006514A2 (es) 2020-10-29 2023-05-17 Agonista de receptor de melanocortina-4 amorfo

Country Status (12)

Country Link
EP (1) EP4219471A4 (es)
JP (1) JP2023548162A (es)
KR (1) KR20220057469A (es)
CN (1) CN116419757A (es)
AU (1) AU2021370071B2 (es)
CA (1) CA3195214A1 (es)
CL (1) CL2023001221A1 (es)
CO (1) CO2023006514A2 (es)
IL (1) IL302425A (es)
MX (1) MX2023004654A (es)
PE (1) PE20231379A1 (es)
WO (1) WO2022092908A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240059652A1 (en) * 2020-12-22 2024-02-22 Lg Chem, Ltd. Amorphous melanocortin receptor agonist and method for preparing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505435A (ja) * 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
WO2002059107A1 (en) * 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
JP4795965B2 (ja) * 2003-11-12 2011-10-19 エルジー・ライフ・サイエンシーズ・リミテッド メラノコルチン受容体のアゴニスト
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
KR20190141649A (ko) 2017-02-08 2019-12-24 틸레이, 인크. 대마의 저압 복사 에너지 프로세싱을 위한 방법 및 장치
PT3953327T (pt) * 2019-11-07 2024-02-05 Lg Chemical Ltd Agonistas do recetor de melanocortina-4

Also Published As

Publication number Publication date
PE20231379A1 (es) 2023-09-07
WO2022092908A1 (ko) 2022-05-05
MX2023004654A (es) 2023-05-18
IL302425A (en) 2023-06-01
AU2021370071A1 (en) 2023-06-01
JP2023548162A (ja) 2023-11-15
CA3195214A1 (en) 2022-05-05
EP4219471A4 (en) 2024-03-13
AU2021370071B2 (en) 2024-01-11
CN116419757A (zh) 2023-07-11
EP4219471A1 (en) 2023-08-02
CL2023001221A1 (es) 2023-11-03
KR20220057469A (ko) 2022-05-09

Similar Documents

Publication Publication Date Title
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006517A2 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006514A2 (es) Agonista de receptor de melanocortina-4 amorfo
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
BR112018010355A2 (pt) método para produzir um substrato, substrato, produto, e, uso de um substrato.
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
UY36746A (es) Método para la síntesis de derivados de rapamicina
MY196762A (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
MX2022009281A (es) Inhibidores de rorgamma.
BR112012020782A2 (pt) composto, e, processo para preparar um composto
BR112018074287A2 (pt) processo para preparação de eribulina e intermediários da mesma
BR112023022863A2 (pt) Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
CY1115409T1 (el) Νεο πολυμορφο του υδροχλωρικου αλατος του (4-υδροξυκαρβαμοϋλ-φαινυλ)καρβαμικου (6-διμεθυλαμινο μεθυλ-2-ναφθαλενυλ)εστερα
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
RU2014126321A (ru) Производное пароксетина
BR112018009029A8 (pt) corante, método para a produção de um corante, composição, artigo manufaturado e uso de um corante
MX2023013129A (es) Forma cristalina iv de sales de acidos organicos del compuesto agonista del receptor de melanocortina y metodo de preparacion de este.
MX2023013128A (es) Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
MX2019007573A (es) Proceso de sisntesis de ditiocarbamatos ciclicos funcionalizados.
WO2009016984A1 (ja) 化合物及びその製造方法